Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Morphic Holding Inc (NQ: MORF )

50.79 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 50.79
Bid (Size) 44.35 (1)
Ask (Size) 58.16 (1)
Prev. Close 50.79
Today's Range 50.79 - 50.79
52wk Range 23.03 - 63.08
Shares Outstanding 36,415,045
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference
From Morphic Therapeutic
Via GlobeNewswire

Performance

YTD
+94.08%
+94.08%
1 Month
-7.54%
-7.54%
3 Month
-16.81%
-16.81%
6 Month
+32.02%
+32.02%
1 Year
+79.72%
+79.72%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
Via Benzinga
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 7/17
Via Investor Brand Network
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
From Morphic Therapeutic
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
Via Benzinga
3 Stocks That Could Skyrocket by This Time Next Summer
Via InvestorPlace
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 6/5
Via Investor Brand Network
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 5/10
Via Investor Brand Network
3 Biotech Buyout Targets to Watch
Via The Motley Fool
Morphic to Present at the Jefferies Global Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis
From Morphic Therapeutic
Via GlobeNewswire
4 Analysts Have This to Say About Morphic Holding
Via Benzinga
Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Morphic Therapeutic
Via GlobeNewswire
More Than $47M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering
From Morphic Therapeutic
Via GlobeNewswire
Morphic Therapeutic Announces Proposed Public Offering
From Morphic Therapeutic
Via GlobeNewswire
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Morphic Therapeutic's Ulcerative Colitis Candidate Shows Clinically Meaningful Improvements Across Measures, Stock Soars
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
From Morphic Therapeutic
Via GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
From Morphic Therapeutic
Via GlobeNewswire
Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
From Morphic Therapeutic
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.